

OMESTI BERHAD
[Registration No. 200001028094 (530701-T)]
(Incorporated in Malaysia)

MINUTES of the 23rd Annual General Meeting of Omesti Berhad (“**Omesti**” or “**the Company**”) held on Tuesday, 19 September 2023 at 3.00 pm, as a virtual meeting via live streaming broadcast from Redwood Meeting Room, Ho Hup Tower – Aurora Place, 2-09-01 – Level 9, Plaza Bukit Jalil, No. 1, Persiaran Jalil 1, Bandar Bukit Jalil, 57000 Kuala Lumpur.

Directors

PRESENT : YAM Tunku Zain Al-'Abidin Ibni Tuanku Muhriz
Chairman/ Independent Non-Executive Director
Dato' Sri Thong Kok Khee (*Participated remotely from his location*)
Deputy Chairman/Non-Independent Non-Executive Director
Ms Mah Xian-Zhen
Non-Independent Non-Executive Director
Mr Monteiro Gerard Clair
Non-Independent Non-Executive Director
Mr Tan Wee Hoong (Robin)
Independent Non-Executive Director
Mr Danny Hoe Kam Thong
Independent Non-Executive Director

Management

Mr Wong Kaixuan
Finance Manager

BY INVITATION : Ms Koo Swee Lin
Representing BDO PLT, the External Auditors

SHAREHOLDERS/ : As per Summary of Attendance List via Remote Participation and
PROXIES/AUTHORISED Voting at <https://agm.omesti.com>
REPRESENTATIVE

IN ATTENDANCE : Ms Lim Shook Nyee (Agnes)
Group Company Secretary

1. OPENING ADDRESS BY THE CHAIRMAN

YAM Tunku Zain Al-'Abidin Ibni Tuanku Muhriz (“**Tunku Chairman**”), the Chairman of the Company welcomed the shareholders, proxies and invitees for participating remotely from various locations through live streaming webcast to the Company’s 23rd Annual General Meeting (“**23rd AGM**” or “**Meeting**”).

Tunku Chairman added that the 23rd AGM was convened via live streaming and online remote voting using the Remote Participation and Electronic Voting (“**RPEV**”) facilities in accordance with Section 327 of the Companies Act 2016, and the Guidance Notes on the Conduct of General Meetings issued by Securities Commission of Malaysia.

2. QUORUM & NOTICE OF MEETING

With the requisite quorum present pursuant to Clause 57 of the Company's Constitution, Tunku Chairman called the Meeting to order.

The Notice of 23rd AGM dated 28 July 2023 as contained on pages 62 to 65, Volume I of the Company's Annual Report 2023, which had been sent to all shareholders of the Company, Bursa Malaysia Securities Berhad and the Auditors of the Company, was taken as read.

3. INTRODUCTION

Tunku Chairman informed that all Directors of the Company, the Company Secretary, the Finance Manager, the external auditors, BDO PLT and the poll administrator, Red Ape Solutions Sdn Bhd were present at the Broadcast Venue except for Dato' Sri Thong Kok Khee who was participated remotely from his location.

4. VOTING PROCEDURES

Tunku Chairman informed that the voting at the 23rd AGM would be conducted by way of poll through electronic voting using RPEV facilities, i.e. e-polling, in line with the Main Market Listing Requirements of Bursa Malaysia Securities Berhad. He further informed that the shareholders and proxies could vote on all the five (5) resolutions from the commencement of the activation of the voting platform until the closure of the voting session to be announced by Tunku Chairman.

Tunku Chairman highlighted that the Company had appointed Red Ape Solutions Sdn Bhd as the Poll Administrator, to conduct the e-polling process and Quantegic Services Sdn Bhd as the Scrutineers to verify the poll results. The polling process for all the 5 resolutions would be conducted after the completion of the deliberation of all items to be transacted at the 23rd AGM.

Tunku Chairman further highlighted that both Mr Wong Kaixuan and Ms Tee Hong Cheat, being shareholders of the Company, would be the proposer and seconder for all the 5 resolutions to be tabled at the 23rd AGM.

5. PRESENTATION ON QUESTIONS RAISED BY MINORITY SHAREHOLDERS WATCH GROUP

Tunku Chairman informed that the Company had received several questions from the Minority Shareholders Watch Group ("MSWG") via its letter dated 12 September 2023 and the Company's responses to the same were displayed on the screen, for information of all the members at the Meeting.

A copy each of the said letter and the corresponding responses from the Company to MSWG are attached to this Minutes as Annexure A.

6. **AGENDA 1**
TO RECEIVE AUDITED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2023 TOGETHER WITH THE REPORTS OF THE DIRECTORS AND AUDITORS THEREON

Tunku Chairman explained that the Audited Financial Statements for the financial year ended 31 March 2023 (“**AFS 2023**”) together with the Reports of the Directors and Auditors thereon, were meant for discussion only. The AFS 2023 did not require shareholders’ approval under the provisions of Section 248(1) and (2) of the Companies Act 2016.

Tunku Chairman then declared that the AFS 2023 together with the Reports of the Directors and Auditors thereon, be received.

7. **ORDINARY RESOLUTION 1**
PAYMENT OF DIRECTORS’ FEES AND BENEFITS AMOUNTING TO RM719,000 FOR THE PERIOD FROM 20 SEPTEMBER 2023 UNTIL THE CONCLUSION OF THE NEXT ANNUAL GENERAL MEETING

Tunku Chairman proceeded with Ordinary Resolution 1 to seek shareholders’ approval on the payment of Directors’ fees and benefits to Non-Executive Directors of up to an amount of RM719,000 for the period from 20 September 2023 until the conclusion of the next Annual General Meeting of the Company.

Tunku Chairman, being the Interested Director for Ordinary Resolution 1, had abstained from deliberation and voting in respect of his shareholdings on Ordinary Resolution 1.

8. **ORDINARY RESOLUTION 2**
RE-ELECTION OF YANG AMAT MULIA TUNKU ZAIN AL-‘ABIDIN IBNI TUANKU MUHRIZ AS A DIRECTOR PURSUANT TO CLAUSE 78 OF THE COMPANY’S CONSTITUTION

Tunku Chairman proceeded to the next Agenda, Ordinary Resolutions 2 and 3 in respect of the re-election of Directors pursuant to Clause 78 of the Company’s Constitution. The Meeting noted that each re-election of Director would be voted on individually.

As the Ordinary Resolution 2 was related to re-election of Tunku Chairman as a Director of the Company, Tunku Chairman passed over the chair to Mr Tan Wee Hoong (Robin) (“**Mr Robin Tan**”).

Mr Robin Tan informed the Meeting that Ordinary Resolution 2 was in relation to the re-election of Yang Amat Mulia Tunku Zain Al-‘Abidin Ibni Tuanku Muhriz, who retired in accordance with Clause 78 of the Company’s Constitution and being eligible, had offered himself for re-election.

Mr Robin Tan then handed back the Chair to Tunku Chairman.

9. ORDINARY RESOLUTION 3
RE-ELECTION OF MR TAN WEE HOONG (“MR ROBIN TAN”) AS A DIRECTOR
PURSUANT TO CLAUSE 78 OF THE COMPANY’S CONSTITUTION

Tunku Chairman proceeded with Ordinary Resolution 3 in relation to the re-election of Mr Robin Tan, who retired in accordance with Clause 78 of the Company’s Constitution and being eligible, had offered himself for re-election.

10. ORDINARY RESOLUTION 4
RE-APPOINTMENT OF BDO PLT AS AUDITORS OF THE COMPANY

Tunku Chairman continued with Ordinary Resolution 4 on the re-appointment of BDO PLT, who have indicated their willingness to continue in office, as Auditors of the Company for the ensuing year until the conclusion of the next Annual General Meeting and to authorise the Directors to fix their remuneration.

11. SPECIAL BUSINESS - ORDINARY RESOLUTION 5
PROPOSED RENEWAL OF EXISTING SHAREHOLDERS’ MANDATE FOR RECURRENT
RELATED PARTY TRANSACTIONS OF A REVENUE OR TRADING NATURE (“RRPT”)
(“PROPOSED MANDATE”)

Tunku Chairman informed that the next item under special business on Ordinary Resolution 5 was pertaining to the Proposed Mandate.

Tunku Chairman explained that the Proposed Mandate would enable Omesti Group to enter into the RRPT which are necessary for the day-to-day operations of Omesti Group as detailed in the Circular to Shareholders dated 28 July 2023.

It was noted that the interested Director and deemed Major Shareholder, namely Dato’ Sri Thong Kok Khee and interested persons connected with him as detailed in the Circular to Shareholders dated 28 July 2023 would abstain from voting in respect of their direct and indirect shareholdings on the Proposed Mandate.

12. ANY OTHER BUSINESS

The Meeting noted that no notice was received to transact any other business.

13. QUESTIONS AND ANSWERS (“Q&A”) SESSION

Following the presentation of all resolutions in the agenda, Tunku Chairman declared the commencement of the Q&A session.

Tunku Chairman informed that the Company had not received any questions from the shareholders during the 23rd AGM.

14. E-POLLING PROCESS

Tunku Chairman informed that the Meeting would proceed with the electronic poll voting i.e. e-polling for all the proposed Ordinary Resolutions 1 to 5. He then briefed the Meeting on the procedures on the electronic polling process.

The Meeting was adjourned at 3.10 p.m. for shareholders and proxies to cast their votes.

15. ANNOUNCEMENT OF POLL RESULTS

Tunku Chairman resumed the Meeting at 3.35 p.m. to announce the polling results in respect of the 5 resolutions which had been tabled at the 23rd AGM. He highlighted that the polling results had been verified by the Scrutineers, Quantegic Services Sdn Bhd. The results were displayed on the screen and based on the polling results, Tunku Chairman declared that all the 5 resolutions as set out in the Notice of the 23rd AGM dated 28 July 2023 were **CARRIED** as follows and a copy of the polling results presented at the Meeting is attached to this Minutes as Annexure B:-

Ordinary Resolution 1**Approval for Payment of Directors' Fees and Benefits to Non-Executive Directors**

Voted	For	Against
No. of Shareholders	33	15
No. of Shares	191,968,362	6,973
% of Voted Shares	99.99637	0.00363

“THAT the payment of Directors’ Fees and benefits to Non-Executive Directors of up to an amount of RM719,000 for the period from 20 September 2023 until the conclusion of the next Annual General Meeting (AGM) of the Company be and is hereby approved.”

Ordinary Resolution 2**Re-Election of Y.A.M. Tunku Zain Al-‘Abidin Ibni Tuanku Muhriz as a Director**

Voted	For	Against
No. of Shareholders	55	6
No. of Shares	299,739,347	6,498
% of Voted Shares	99.99783	0.00217

“THAT Y.A.M. Tunku Zain Al-‘Abidin Ibni Tuanku Muhriz who retired by rotation pursuant to Clause 78 of the Company’s Constitution and being eligible, be and is hereby re-elected as a Director of the Company.”

Ordinary Resolution 3**Re-Election of Mr Tan Wee Hoong as a Director**

Voted	For	Against
No. of Shareholders	57	5
No. of Shares	301,369,349	6,496
% of Voted Shares	99.99784	0.00216

“THAT Mr Tan Wee Hoong who retired by rotation pursuant to Clause 78 of the Company’s Constitution and being eligible, be and is hereby re-elected as a Director of the Company.”

Ordinary Resolution 4
Re-Appointment of BDO PLT as Auditors

Voted	For	Against
No. of Shareholders	57	5
No. of Shares	301,369,349	6,496
% of Voted Shares	99.99784	0.00216

“THAT BDO PLT be and are hereby re-appointed as Auditors of the Company for the next ensuing year to hold office until the conclusion of the next Annual General Meeting at a remuneration to be determined by the Directors.”

Ordinary Resolution 5
Proposed Renewal of Existing Shareholders’ Mandate for Recurrent Related Party Transactions of a Revenue or Trading Nature

Voted	For	Against
No. of Shareholders	50	6
No. of Shares	247,509,787	6,498
% of Voted Shares	99.99737	0.00263

“THAT the Company and/or its subsidiaries be and is/are hereby authorised to enter into recurrent related party transactions from time to time with Related Parties who may be a Director, a major shareholder of the Company and/or its subsidiaries or a person connected with such a Director or major shareholder, as specified in section 2.3 of the Circular to Shareholders dated 28 July 2023 subject to the following:-

- (i) the transactions are of a revenue or trading nature which are necessary for the day-to-day operations of the Company and/or its subsidiaries and are transacted on terms consistent or comparable with market or normal trade practices and/or based on normal commercial terms and on terms not more favourable to the Related Parties than those generally available to the public and are not to the detriment of the minority shareholders; and***
- (ii) disclosure is made in the annual report of the aggregate value of transactions conducted during the financial year pursuant to the shareholders’ mandate in accordance with the Main Market Listing Requirements of Bursa Malaysia Securities Berhad;***

THAT the mandate given by the shareholders of the Company shall only continue to be in force until the conclusion of the next AGM of the Company or the expiry of the period within which the next AGM is required to be held pursuant to Section 340(2) of the Companies Act 2016 (the Act) (but shall not extend to such extension as may be allowed pursuant to Section 340(4) of the Act); unless revoked or varied by Ordinary Resolution of the shareholders of the Company in general meeting, whichever is the earlier;

AND THAT the Directors of the Company be authorised to complete and carry out such acts and actions as they may consider expedient or necessary to give effect to the shareholders’ mandate.”

16. CLOSURE

There being no other business to be transacted, the Meeting ended at 3.38 p.m. with a vote of thanks to Tunku Chairman.

Tunku Chairman thanked all members present for their support and participation at the 23rd AGM.

Confirmed as a correct record of proceedings,



CHAIRMAN

Date: 17 October 2023

At Kuala Lumpur



MINORITY SHAREHOLDERS WATCH GROUP
Shareholder Activism and Protection of Minority Interest

12 September 2023

BY EMAIL/FAX/HAND

The Board of Directors

OMESTI BERHAD

Ho Hup Tower – Aurora Place
2-07-01 – Level 7, Plaza Bukit Jalil
No. 1, Persiaran Jalil 1
Bandar Bukit Jalil
57000 Kuala Lumpur

Attention: Ms. Lim Shook Nyee
Company Secretary

Dear Directors,

Re: 23rd Annual General Meeting (“AGM”) of Omesti Berhad (“Omesti” or the “Company”) to be held on Tuesday, 19 September 2023

In the interest of minority shareholders and all other stakeholders of the Company, we would like to raise the following questions: -

Operational & Financial Matters

1. The first laboratory, located in Penang, Medilabz Signature is operated on behalf of the JVC by Mediven® technicians, and backed by Mediven’s comprehensive diagnostics technology and expertise. The test laboratory is working closely with clinics to provide screening services to the residents and workforce in the surrounding areas. (page 4 of Volume 1, AR2023)

How and to what extent is the test laboratory contributing to the Group’s revenue? How many clinics is the test laboratory currently working with?

2. The Healthcare Services segment revenue for the financial year increased by 47.9% from RM15.37 million to RM22.74 million, mainly due to increase in outlets and sales (page 8 of Volume 1, AR2023). Although revenue increased substantially, the Healthcare Services segment recorded a loss before tax of RM0.69 million (2022: profit before tax of RM2.57 million) (Note 4(a), pages 31&32 of Volume 2, AR2023).

BADAN PENGAWAS PEMEGANG SAHAM MINORITI BERHAD

Incorporated in Malaysia Registration No: 200001022382 (524989-M)

LEVEL 23, UNIT 23-2, MENARA AIA SENTRAL

No. 30, JALAN SULTAN ISMAIL

50250 KUALA LUMPUR

TEL: (603) 27320010

E-mail: mwatch@mswg.org.my Website: www.mswg.org.my

- (a) Given that the Healthcare Services segment's revenue increased significantly, why did it turn loss making?
- (b) To-date, how far off is the Group's Healthcare Services segment from returning to profitability?
3. On 22 February 2023, Bemed (PTJ) Sdn. Bhd. ("PTJ"), a 70% indirectly-owned subsidiary of the Company acquired 100% of the entire issued and paid-up share capital of RJ Drugstore Sdn. Bhd. ("RJ"), a company incorporated in Malaysia that is engaged in the trading of pharmaceutical products for a total consideration of RM1.45 million. The Contingent considerations were as follows (Note 7 (d)(ii)(1), page 46 of Volume 2, AR2023):

– RM200,000 subject to achievement of net profit guarantee of RM200,000 based on the audited results of RJ for the financial year ended 31 December 2022 ("FYE 2022")
– RM200,000 subject to achievement of net profit guarantee of RM200,000 based on the audited results of RJ for the financial year ended 31 December 2023 ("FYE 2023")
– RM150,000 subject to achievement of net profit guarantee of RM200,000 based on the audited results of RJ for the financial year ended 31 December 2024 ("FYE 2024")

For FYE 2022, was the net profit guarantee of RM200,000 based on the audited results of RJ achieved? To-date, how far-off is the net profit guarantee of RM200,000 being achieved for financial year ending 31 December 2023?

4. Pursuant to the Share Sale Agreement dated 10 November 2021 on the acquisition of Bemed Group, Omesti Holdings Berhad ("OHB") and the vendors had entered into a Profit Guarantee Agreement, whereby the vendors shall guarantee that the actual aggregate profit after tax ("PAT") of Bemed Group for the financial year ending ("FYE") 2022, 2023 and 2024 shall be collectively RM9 million, with an aggregate PAT of Bemed Group of not less than RM2.5 million per financial year. The aggregate PAT of Bemed Group for FYE 2022 is determined based on the results from 1 January 2021 till 31 March 2022, whereas FYE 2023 and FYE 2024 will be determined based on results from 1 April 2022/2023 to 31 March 2023/2024. (Note 7(d)(ii)(4), page 52 of Volume 2, AR2023)

BADAN PENGAWAS PEMEGANG SAHAM MINORITI BERHAD

Incorporated in Malaysia Registration No: 200001022382 (524989-M)

LEVEL 23, UNIT 23-2, MENARA AIA SENTRAL

No. 30, JALAN SULTAN ISMAIL

50250 KUALA LUMPUR

TEL: (603) 27320010

E-mail: mwatch@mswg.org.my Website: www.mswg.org.my

What was the PAT achieved by Bemed Group for FYE 2022 and FYE 2023?

5. Impairment allowance for amounts owing by related parties of the Group amounted to RM1.81 million were written off (Note 21, page 90 of Volume 2, AR2023).
 - (a) Why were the impairment allowance for amounts owing by related parties of the Group being written off?
 - (b) What comprises these amounts owing by related parties that have been written off?
 - (c) What were the measures taken to recover the RM1.81 million prior to being written off?
6. The Group's capital commitments approved but not contracted for amounted to RM4.24 million. (Note 34, page 109 of Volume 2, AR2023)

For which business segments of the Group is the capital commitments of RM4.24 million earmarked for? Please provide brief details and breakdown.

Please present the questions raised herein, and the related answers, to the shareholders present at the forthcoming AGM. At the same time, we await a written reply as soon as possible for our records.

Thank you.

Yours sincerely



Devanesan Evanson

Chief Executive Officer

DE/RF/ECYL/OMESTI/AGM 2023

BADAN PENGAWAS PEMEGANG SAHAM MINORITI BERHAD

Incorporated in Malaysia Registration No: 200001022382 (524989-M)

LEVEL 23, UNIT 23-2, MENARA AIA SENTRAL

No. 30, JALAN SULTAN ISMAIL

50250 KUALA LUMPUR

TEL: (603) 27320010

E-mail: mswatch@mswg.org.my Website: www.mswg.org.my

OMESTI BERHAD
(200001028094 (530701-T))
23rd ANNUAL GENERAL MEETING
Tuesday, 19 September 2023

**QUESTIONS RAISED BY THE
MINORITY SHAREHOLDERS WATCH GROUP**

Operational & Financial Matters

- Q1. The first laboratory, located in Penang, Medilabz Signature is operated on behalf of the JVC by Mediven® technicians, and backed by Mediven’s comprehensive diagnostics technology and expertise. The test laboratory is working closely with clinics to provide screening services to the residents and workforce in the surrounding areas. (page 4 of Volume 1, AR2023)**

How and to what extent is the test laboratory contributing to the Group’s revenue? How many clinics is the test laboratory currently working with?

Answer:

The test laboratory contributed revenue of RM8,658 to the Group for FY2023.

As for now , the test laboratory is working with 4 clinics and a government associate.

- Q2. The Healthcare Services segment revenue for the financial year increased by 47.9% from RM15.37 million to RM22.74 million, mainly due to increase in outlets and sales (page 8 of Volume 1, AR2023). Although revenue increased substantially, the Healthcare Services segment recorded a loss before tax of RM0.69 million (2022: profit before tax of RM2.57 million) (Note 4(a), pages 31&32 of Volume 2, AR2023).**
- (a) Given that the Healthcare Services segment’s revenue increased significantly, why did it turn loss making?**
- (b) To-date, how far off is the Group’s Healthcare Services segment from returning to profitability?**

Answer:

- a) Part of the Healthcare Services segment's PBT in FY2022 was driven by Vaccine and RTK Sales. Vaccine and RTK contributed RM1.4M and RM1.1M in GP respectively in FY2022. Also, the new outlets contributed loss before tax amounting to (RM364K) in FY2023. Hence, the Healthcare segment turned loss making in FY2023.
- b) Management has projected that the Group's Healthcare services segment would return to profitability in FY2025.

Q3. On 22 February 2023, Bemed (PTJ) Sdn. Bhd. ("PTJ"), a 70% indirectly-owned subsidiary of the Company acquired 100% of the entire issued and paid-up share capital of RJ Drugstore Sdn. Bhd. ("RJ"), a company incorporated in Malaysia that is engaged in the trading of pharmaceutical products for a total consideration of RM1.45 million. The Contingent considerations were as follows (Note 7 (d)(ii)(1), page 46 of Volume 2, AR2023):

- RM200,000 subject to achievement of net profit guarantee of RM200,000 based on the audited results of RJ for the financial year ended 31 December 2022 ("FYE 2022")
- RM200,000 subject to achievement of net profit guarantee of RM200,000 based on the audited results of RJ for the financial year ended 31 December 2023 ("FYE 2023")
- RM150,000 subject to achievement of net profit guarantee of RM200,000 based on the audited results of RJ for the financial year ended 31 December 2024 ("FYE 2024")

For FYE 2022, was the net profit guarantee of RM200,000 based on the audited results of RJ achieved? To-date, how far-off is the net profit guarantee of RM200,000 being achieved for financial year ending 31 December 2023?

Answer:

The FYE2022 net profit guarantee of RM200,000 was not met.

RJ is unlikely to achieve the net profit guarantee of FYE2023.

- Q4. Pursuant to the Share Sale Agreement dated 10 November 2021 on the acquisition of Bemed Group, Omesti Holdings Berhad (“OHB”) and the vendors had entered into a Profit Guarantee Agreement, whereby the vendors shall guarantee that the actual aggregate profit after tax (“PAT”) of Bemed Group for the financial year ending (“FYE”) 2022, 2023 and 2024 shall be collectively RM9 million, with an aggregate PAT of Bemed Group of not less than RM2.5 million per financial year. The aggregate PAT of Bemed Group for FYE 2022 is determined based on the results from 1 January 2021 till 31 March 2022, whereas FYE 2023 and FYE 2024 will be determined based on results from 1 April 2022/2023 to 31 March 2023/2024. (Note 7(d)(ii)(4), page 52 of Volume 2, AR2023)**

What was the PAT achieved by Bemed Group for FYE 2022 and FYE 2023?

Answer:

FYE 2022 : PAT after excluding extraordinary items i.e. disposal gains, dividend income, rental income/expenses of disposed property and initial expenses of a new outlet is RM2.5 million.

FYE 2023 : Loss After Tax (LAT) of (RM 0.8 million).

- Q5. Impairment allowance for amounts owing by related parties of the Group amounted to RM1.81 million were written off (Note 21, page 90 of Volume 2, AR2023).**

- (a) Why were the impairment allowance for amounts owing by related parties of the Group being written off?**
- (b) What comprises these amounts owing by related parties that have been written off?**
- (c) What were the measures taken to recover the RM1.81 million prior to being written off?**

Answer:

- a) The impairment allowance written off was relating to an amount owing by Microlink Solutions Pte. Ltd. (fka Formis Labs Singapore Pte. Ltd.), previously an indirect wholly-owned subsidiary of the Group, disposed to Microlink Solutions Bhd on 4 July 2022. The previously written off amounts were internal and were previously eliminated as part of the Group. Subsequent to the disposal, the written off amount became external and hence was reflected in Note 21.

- b) The amount was relating to advances to Microlink Solutions Pte. Ltd.

- c) Since the amount previously was an internal debt, management had taken steps previously to assess its collectibility internally. It was written off after this amount had been assessed to be uncollectible.

Q6. The Group's capital commitments approved but not contracted for amounted to RM4.24 million. (Note 34, page 109 of Volume 2, AR2023)

For which business segments of the Group is the capital commitments of RM4.24 million earmarked for? Please provide brief details and breakdown.

Answer:

RM4.24 million is earmarked for the healthcare segment. Of the RM4.24 million:

1. RM4.05 million is earmarked for the Diagnostic Centre of Aurora 360 Sdn Bhd for renovation, and software and computer equipment.
2. RM0.19 million is earmarked for opening of a new pharmacy retail outlet for renovation costs, furniture & fittings, signboard, office equipment, and software and computer equipment.

OMESTI BERHAD 23RD AGM
OMESTI BERHAD
Tuesday, September 19th, 2023 at 3:00 PM Malaysia Time
Results on voting by poll

RESOLUTION (s)	Nos of Records	VOTE FOR		Nos of Records	VOTE AGAINST		TOTAL	
		No of units	%		No of units	%	No of units	%
To approve the payment of Directors Fees and benefits to Non-Executive Directors of up to an amount of RM719,000 for the period from 20 September 2023 until the conclusion of the next Annual General Meeting (AGM) of the Company.	33	191,968,362	99.99637	15	6,973	0.00363	191,975,335	100.00000
To re-elect Y.A.M. Tunku Zain Al-'Abidin Ibni Tuanku Muhriz who retires pursuant to Clause 78 of the Company's Constitution and being eligible, has offered himself for re-election.	55	299,739,347	99.99783	6	6,498	0.00217	299,745,845	100.00000
To re-elect Mr Tan Wee Hoong who retires pursuant to Clause 78 of the Company's Constitution and being eligible, has offered himself for re-election.	57	301,369,349	99.99784	5	6,496	0.00216	301,375,845	100.00000
To re-appoint BDO PLT as Auditors of the Company for the ensuing year and to authorise the Directors to fix their remuneration.	57	301,369,349	99.99784	5	6,496	0.00216	301,375,845	100.00000
Proposed Renewal of Existing Shareholders' Mandate for Recurrent Related Party Transactions of a Revenue or Trading Nature.	50	247,509,787	99.99737	6	6,498	0.00263	247,516,285	100.00000

